Vera Therapeutics (VERA) Stock Forecast & Price Target

Vera Therapeutics is positioned favorably by the FDA’s July 7 accelerated approval of Trutakna, which validates atacicept as the first approved agent targeting both BAFF and APRIL in IgAN and strengthens the company’s clinical and regulatory story. Management still expects the ORIGIN 3 eGFR readout in 3Q26 to support a 4Q26 sBLA filing for full approval, and a positive result could improve formulary access and adoption because payers and nephrologists may prefer a fully approved therapy backed by eGFR data. Commercially, the IgAN market appears to be expanding, while peer launch data such as Voyxact’s 180, 880, and 960 patient start forms across its first three quarters and Filspari’s 2,012 2Q26 PSFs suggest meaningful demand potential for Trutakna.

Vera Therapeutics is facing a difficult commercialization and regulatory path because atacicept must compete against stronger-than-expected Voyxact data, where monthly dosing and a compelling eGFR profile raise the bar for differentiation and make weekly administration a commercial disadvantage. The company’s outlook is further pressured by financial dependence on external capital, as it reported 2Q26 GAAP EPS of $(1.52), exited 2Q26 with $499M in cash/equivalents, and still may need additional funding despite $425M available under its credit facility. With peak IgAN penetration cut to 15% from 20% and modeled revenue now $16M in 2026 and $3.8B in 2033, the stock’s fundamentals look constrained by execution risk, possible label limitations, and intensifying competition.